Plectin’s association with plasmalemmal AQP4 aggregates, its increased cell surface localization, and its release from GBM cell cultures, suggest that plectin may serve as a potential biomarker and candidate molecule for the diagnosis and treatment of GBMs. The gene discussed is PLEC; the disease is glioblastoma.